| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S00393-014-1479-8 |
| P698 | PubMed publication ID | 25962452 |
| P2093 | author name string | C D Cohen | |
| H D Rupprecht | |||
| M Zänker | |||
| P2860 | cites work | The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis | Q28140438 |
| 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides | Q28276589 | ||
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011. | Q30764638 | ||
| Normotensive renal failure in systemic sclerosis | Q33436102 | ||
| Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis | Q33556875 | ||
| Long-term outcomes of scleroderma renal crisis | Q33921627 | ||
| Sarcoidosis in native and transplanted kidneys: incidence, pathologic findings, and clinical course | Q34374430 | ||
| Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature | Q34450880 | ||
| Scleroderma renal crisis: patient characteristics and long-term outcomes | Q34643730 | ||
| Histopathologic classification of ANCA-associated glomerulonephritis | Q34660132 | ||
| Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis | Q34975939 | ||
| Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study | Q35094863 | ||
| Rituximab versus cyclophosphamide for ANCA-associated vasculitis | Q35109118 | ||
| Treatment of hepatitis C: a systematic review | Q35223637 | ||
| Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus | Q35551137 | ||
| Renal manifestations of systemic autoimmune disease: diagnosis and therapy | Q35781694 | ||
| Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab | Q35852535 | ||
| The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. | Q36009013 | ||
| Cardiovascular co-morbidity in rheumatic diseases | Q36835851 | ||
| Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force | Q36958222 | ||
| EULAR recommendations for the management of primary small and medium vessel vasculitis. | Q37138800 | ||
| Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis | Q37212339 | ||
| The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy | Q37726149 | ||
| Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. | Q37853275 | ||
| The cryoglobulinaemias | Q37922370 | ||
| Cryoglobulinemia vasculitis: an update | Q38063731 | ||
| Loss of renal function causes premature aging of the immune system. | Q38185251 | ||
| Everything you need to know about distal renal tubular acidosis in autoimmune disease | Q38200512 | ||
| Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health | Q38206017 | ||
| Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker | Q38455102 | ||
| Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients | Q40394968 | ||
| Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis | Q41676109 | ||
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
| Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome | Q43432949 | ||
| Clinical epidemiology of cardiovascular disease in chronic renal disease | Q43631482 | ||
| Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. | Q43815857 | ||
| Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | Q43993205 | ||
| Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. | Q45368252 | ||
| Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia | Q45410788 | ||
| Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. | Q46003173 | ||
| Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. | Q46006712 | ||
| Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. | Q46769274 | ||
| Renal involvement and followup of 130 patients with primary Sjögren's syndrome | Q46846181 | ||
| Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study | Q46847961 | ||
| Q: Should target natriuretic peptide levels be used for outpatient management of chronic heart failure? | Q48727898 | ||
| Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. | Q50559814 | ||
| Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. | Q50865067 | ||
| Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. | Q50918468 | ||
| [Nephropathy in patients with mixed connective tissue disease] | Q72563039 | ||
| Impaired cellular immune function in patients with end-stage renal failure | Q73201646 | ||
| Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy | Q73284276 | ||
| Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group | Q73740085 | ||
| Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports | Q77800110 | ||
| Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland | Q77989665 | ||
| Vaccination and chronic kidney disease | Q80161999 | ||
| Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study | Q80305151 | ||
| Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis | Q80526747 | ||
| Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear | Q86651438 | ||
| Chapter 12: Lupus nephritis | Q87393398 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | rheumatism | Q684924 |
| P1104 | number of pages | 12 | |
| P304 | page(s) | 310-321 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | Zeitschrift fuer Rheumatologie | Q15763293 |
| P1476 | title | Prognosis and therapy of inflammatory rheumatic diseases : Impact of renal manifestations | |
| P478 | volume | 74 |
| Q47230521 | Inhibition of plasma kallikrein-kinin system to alleviate renal injury and arthritis symptoms in rats with adjuvant-induced arthritis | cites work | P2860 |
Search more.